- Regier DA, Narrow WE, Rae DS et al (1993) The de facto US Mental and Addictive Disorders System: epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 50: 85-94.
- National Health Service Executive (1996) Burdens of disease discussion paper. National Health Service Executive, Leeds.
- Knapp M, Kavanagh S (1997) Economic outcomes and costs in the treatment of schizophrenia. Clin Therapeutics 19: 128-38.
- Weiden PJ, Olfson M (1995) Cost of relapse in schizophrenia. Schizophrenia Bull 21: 419-29.
- Tollefson GD, Beasley CM, Tran PV et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154: 457-65.
- Kane JM (1987) Treatment of schizophrenia Schizophr Bull 13: 133-56.
- Hummer M, Fleischhacker WW (1996) Compliance and outcome in patients treated with antipsychotics: the impact of extrapyramidal symptoms. CNS Drugs 5 (suppl 1): 13-20.
- Needham PL, Atkinson J, Skill MJ, Heal DJ (1996) Zotepine: Preclinical tests predict antipsychotic efficacy and an atypical profile. Psychopharmacol Bull 31: 123-8.
- Roth BL, Craigo SC, Choudray MS et al (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268: 1403-9.
- Leysen JE, Janssen PMF, Schotte A et al (1993) Interaction of antipsychotic drugs with neurotransmitter sites in vitro and in vivo in relation to pharmacological and clinical effects: Role of 5HT2 receptors. Psychopharmacobgy 112: S40-S54.
- Leysen JE, Janssen PMF, Heylen L et al (1998) Receptor interactions of new antipsychotics: relation to pharmacodynamics and clinical effects. Int J Psychiatr Clin Pract 2 (suppl 2): S3-S17.
- Rowley HL, Kilpatrick IC, Needham PL, Heal DJ (1998) Elevation of extracellular cortical noradrenaline may contribute to the antidepressant activity of zotepine: an in vivo microdialysis study in freely-moving rats. Neuropharmacol 37: 937-44.
- Petit M, Raniwalla J, Tweed J et al (1996) A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallelgroup double-blind trial Psychopharmacol Bull 32: 81-7.
- Cooper SJ (1996) Abstract presented at 20th Collegium Internationale Neuropsychopharmacologicum (CINP), Melbourne, Australia, June 23-27.
- Barnas C, Stuppäck C, Miller C et al (1992) Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol. Int Clin Psychopharmacol 7: 23-7.
- Cooper SJ, Butler A, Tweed J, Welch C, Raniwalla J. (2000) Zoterpine in the Prevention of Recurrence: A randomised, double blind placebo-controlled study for chronic schizophrenia. Psychopharmacology 150: 237-43.
- American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM-III-R). APA, Washington, DC.
- Overall JE, Gorham DH (1988) Introduction -- The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 24: 97-9.
- Andreasen NC (1989) The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundation. Br J Psychiatry 155 (Suppl. 7): 49-58.
- Guy W (1976) ECDEU Assessment Manual for Psychopharmacology, revised DHEW Pub. No. (ADM) 76 338. pp. 218-22. Rockville, MD: National Institute of Mental Health.
- Guy W, ECDEU Assessment Manual for Psychopharmacology. Rev. Ed. DHEW Pub. No. (ADM) 76338 Rockville, MD: National Institute of Mental Health, pp. 534-7.
- Simpson GM Angus JSW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 45 (suppl 212): 11-19.
- Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-76.
- Hollander M, Wolfe DA (1973) Nonparametric statistical methods (pp. 33-8). New York Wiley.
- Fleischhacker W, Barnas C, Stuppäck CH et al (1989) Zotepine vs haloperidol in paranoid schizophrenia. Psychopharmacol Bull 25: 97-100.
- Dieterle DM Müller-Spahn F, Ackenheil M (1991) Efficacy and tolerance of zotepine in a double-blind comparison with perazine in schizophrenics. Fortschr Neural Psychiatr 59 (suppl. 1): 18-22.
- Müller-Spahn F, Dieterle DM, Ackenheil M (1991) Clinical efficacy of zotepine in the treatment of schizophrenic negative systems. Fortschr Neural Psychiatr 59 (suppl. 1): 30-5.
The safety and efficacy of zotepine in the treatment of schizophrenia: Results of a one-year naturalistic clinical trial
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.